Abstract
There is increasing evidence of the potential therapeutic utility of glutamate receptor antagonists in the treatment of several neurodegenerative disorders, including stroke and epilepsy. In the last few years noncompetitive AMPA receptor antagonists have received considerable attention due to their therapeutic potentiality. The discovery of GYKI 52466, the prototype of noncompetitive AMPA receptor antagonists endowed with anticonvulsant and neuroprotective properties, induced growing interest on 2,3-benzodiazepine derivatives. This review covers the chemistry and pharmacology of this important class of AMPA receptor antagonists.
Keywords: 2,3-Benzodiazepines, AMPA Receptor, glutamate receptor antagonists, neurodegenerative disorders, Stroke, Epilepsy, Anticonvulsant, Neuroprotective
Mini-Reviews in Medicinal Chemistry
Title: synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Volume: 1 Issue: 3
Author(s): M. Zappala, S. Grasso, N. Micale, S. Polimeni and C. De Micheli
Affiliation:
Keywords: 2,3-Benzodiazepines, AMPA Receptor, glutamate receptor antagonists, neurodegenerative disorders, Stroke, Epilepsy, Anticonvulsant, Neuroprotective
Abstract: There is increasing evidence of the potential therapeutic utility of glutamate receptor antagonists in the treatment of several neurodegenerative disorders, including stroke and epilepsy. In the last few years noncompetitive AMPA receptor antagonists have received considerable attention due to their therapeutic potentiality. The discovery of GYKI 52466, the prototype of noncompetitive AMPA receptor antagonists endowed with anticonvulsant and neuroprotective properties, induced growing interest on 2,3-benzodiazepine derivatives. This review covers the chemistry and pharmacology of this important class of AMPA receptor antagonists.
Export Options
About this article
Cite this article as:
Zappala M., Grasso S., Micale N., Polimeni S. and De Micheli C., synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists, Mini-Reviews in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1389557013406783
DOI https://dx.doi.org/10.2174/1389557013406783 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity
Current Pharmaceutical Design Epigenetic Regulation of Trinucleotide Repeat Expansions and Contractions and the “Biased Embryos” Hypothesis for Rapid Morphological Evolution
Current Genomics Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders
Current Pharmaceutical Design Design and In Vitro Evaluation of a Novel Vaginal Drug Delivery System Based on Gelucire
Current Drug Delivery subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Epileptogenicity and Epileptic Activity: Mechanisms in an Invertebrate Model Nervous System
Current Drug Targets Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Current Medicinal Chemistry The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Dysiherbaine: A New Generation of Excitatory Amino Acids of Marine Origin
Central Nervous System Agents in Medicinal Chemistry Cellular Actions of Gabapentin and Related Compounds on Cultured Sensory Neurones
Current Neuropharmacology Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Development and Optimization of Controlled Porosity Osmotic Tablets of Lamotrigine Solid Dispersion
Recent Patents on Drug Delivery & Formulation Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Conotoxin Superfamily Prediction Using Diffusion Maps Dimensionality Reduction and Subspace Classifier
Current Protein & Peptide Science